Trial Profile
Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2017
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 29 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016.
- 22 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as reported byClinicalTrials.gov record.
- 08 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.